Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $174.26 +3.87%
EPS Growth %: -4.2%
Financial Fact:
Total revenues: 0
Today's EPS Names:
CRMT, More
EPS Growth %: -4.2%
Financial Fact:
Total revenues: 0
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.88, $0.02 better than the analyst estimate of $1.86. Revenue for the quarter came in at $805.5 million versus the consensus estimate of $802.45 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.7-2.8 billion, versus the consensus of $3.41 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- JPMorgan Upgrades Nanya Technology Corp (2408:TT) to Overweight
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
